US$10 million investment into the development and registration of Moxidectin announced

Mar 09, 2015

The Global Health Investment Fund (GHIF) and Medicines Development for Global Health (Medicines Development) announced today a 10 million USD program for the registration of moxidectin for the treatment of river blindness (onchocerciasis).

The GHIF is a private investment fund structured by JPMorgan Chase & Co., the Bill & Melinda Gates Foundation and Lion’s Head Global Partners.

Read the press release.

 

Copyright © 2018 JPMorgan Chase & Co. All rights reserved.